Nevro Sees Unusually Large Options Volume (NVRO)

Nevro Corp (NYSE:NVRO) was the recipient of unusually large options trading activity on Thursday. Traders bought 567 call options on the company. This is an increase of approximately 845% compared to the typical volume of 60 call options.

In related news, Director Wilfred E. Jaeger sold 14,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $83.28, for a total value of $1,204,062.24. Following the completion of the transaction, the director now owns 1,518 shares of the company’s stock, valued at approximately $126,419.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wilfred E. Jaeger sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $80.48, for a total transaction of $804,800.00. Following the completion of the transaction, the director now directly owns 1,518 shares of the company’s stock, valued at approximately $122,168.64. The disclosure for this sale can be found here. Insiders sold a total of 234,116 shares of company stock valued at $18,913,822 in the last ninety days. Company insiders own 12.10% of the company’s stock.

How to Become a New Pot Stock Millionaire

Large investors have recently modified their holdings of the business. Hershey Trust Co. acquired a new stake in shares of Nevro during the 4th quarter valued at $119,000. Public Employees Retirement Association of Colorado acquired a new stake in shares of Nevro during the 4th quarter valued at $160,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Nevro during the 3rd quarter valued at $211,000. Glenmede Trust Co. NA acquired a new stake in shares of Nevro during the 4th quarter valued at $237,000. Finally, HBK Investments L P acquired a new stake in shares of Nevro during the 4th quarter valued at $255,000.

A number of research firms recently commented on NVRO. Goldman Sachs began coverage on shares of Nevro in a research note on Wednesday. They issued a “neutral” rating and a $83.00 price objective for the company. ValuEngine raised shares of Nevro from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Zacks Investment Research lowered shares of Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Nevro in a research note on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $97.44.

Shares of NYSE:NVRO opened at $86.52 on Friday. The firm has a market cap of $2,615.81, a price-to-earnings ratio of -69.22 and a beta of -0.53. Nevro has a 12-month low of $65.00 and a 12-month high of $97.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91.

Nevro (NYSE:NVRO) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $97.96 million for the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative net margin of 11.22% and a negative return on equity of 15.01%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business earned ($0.34) EPS. equities analysts forecast that Nevro will post -0.76 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Nevro Sees Unusually Large Options Volume (NVRO)” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3336721/nevro-sees-unusually-large-options-volume-nvro.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Alibaba Group  Expected to Announce Earnings of $0.92 Per Share
Alibaba Group Expected to Announce Earnings of $0.92 Per Share
Brokerages Expect Sunoco LP  to Post $0.52 Earnings Per Share
Brokerages Expect Sunoco LP to Post $0.52 Earnings Per Share
NVE Co.  Receives Consensus Rating of “Hold” from Brokerages
NVE Co. Receives Consensus Rating of “Hold” from Brokerages
onG.social Price Up 25.6% Over Last 7 Days
onG.social Price Up 25.6% Over Last 7 Days
SwftCoin Market Cap Tops $22.12 Million
SwftCoin Market Cap Tops $22.12 Million
Coupecoin   Trading 8.1% Lower  This Week
Coupecoin Trading 8.1% Lower This Week


© 2006-2018 Ticker Report. Google+.